Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on February 12, 2026.
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.2 pts more than Nifty Midcap 150 and 1.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Biocon's board approved unaudited Q3 FY26 (quarter ended Dec 31, 2025) results. Consolidated revenue from operations grew to Rs 41,730 crore (vs Rs 38,214 crore in Q3 FY25), and 9M FY26 revenue rose to Rs 1,24,104 crore (~14% YoY). However, the company reported a consolidated net loss of Rs 518 crore in Q3 FY26 (vs profit of Rs 811 crore a year ago), largely due to exceptional items of Rs 2,934 crore including advisory/bridge financing costs for the BBL acquisition, Mylan transaction expenses, and labour code gratuity impact. Standalone also slipped to a Rs 764 crore loss from a Rs 5,840 crore profit (which had a one-time Syngene stake sale gain). On the operational front, pre-exceptional operating margins improved both standalone (16.97% to 23.84%) and consolidated (20.59% to 22.78%). The board also gave in-principle approval to acquire the remaining ~2% of Biocon Biologics (BBL) to make it a wholly-owned subsidiary, to be paid via preferential issue of Biocon shares.
While underlying margins and topline look healthy, reported Q3 losses driven by one-time Mylan deal costs and exceptional items may pressure near-term sentiment. Long-term, making BBL a wholly-owned subsidiary simplifies the group structure and gives full earnings benefit of Biocon Biologics to Biocon shareholders.